Gynecological Health

Gynesonics Receives FDA Clearance for its Next Generation Sonata System

Gynesonics, a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids, has received FDA clearance for Sonata System 2.2, which provides new benefits for facilities, physicians and patients. These benefits include a 20% reduction in the smallest ablation size setting, which greatly increases the ability to treat fibroids in tighter anatomical locations, new software advances that…

Anthem Now Covers Hologic’s Acessa Procedure as a Treatment for Fibroids

Hologic’s Acessa procedure is now covered by Anthem Blue Cross Blue Shield, the second largest health plan in the United States. Anthem has updated its medical policy to cover Radiofrequency Ablation (LAP-RFA), which includes the Acessa procedure for women suffering from uterine fibroids. The updated policy creates access to uterine-preserving care for Anthem’s approximately 40 million members in all 50 states, providing…

AOA Dx Secures a Suite of IP Related To Early Detection in Support of its Mission to Transform Ovarian Cancer Diagnostics

AOA Dx has signed an Exclusive License Agreement with Professor H. Uri Saragovi, a Senior Investigator with the Lady Davis Institute at the Jewish General Hospital and Professor at McGill University, to secure a suite of IP related to utilizing gangliosides for early cancer detection through liquid biopsies. A family of gangliosides function as tumor markers, as they are low or absent…

Gynesonics’ Sonata System Is Now Covered by Cigna for the Treatment of Uterine Fibroids

Gynesonics, a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids, announced today that Cigna has released a national coverage policy for treatment of uterine fibroids with the Sonata System.  The Sonata System uses radiofrequency energy to ablate fibroids under real time sonography guidance from within the uterine cavity, utilizing the first and only intrauterine ultrasound…

Auransa and POLARISqb Enter Research Collaboration to Find Treatments for Neglected Women’s Diseases Like Endometriosis and PCOS

Auransa, an artificial intelligence (AI) company developing precision medicines in areas of unmet medical needs, and Polaris Quantum Biotech (POLARISqb), a quantum drug design company, announced a research collaboration addressing therapeutics for neglected diseases disproportionately affecting women. The partnership seeks to discover treatments that may tackle many such diseases, and their complementary expertise promises to seek solutions that elude medical research.  Auransa…

Cigna Now Covers Hologic’s Acessa Procedure for Uterine Fibroids

Women’s health company Hologic has announced a new parntership with Cigna, one of the largest global health insurance service companies. Cigna has updated its medical policy to cover Hologic’s Acessa Laparoscopic Radiofrequency Ablation (Lap-RFA) procedure (CPT code 58674) as medically necessary. This new coverage further validates laparoscopic radiofrequency ablation (Lap-RFA) as a standard of care for uterine fibroids. The Acessa procedure can…

Ark Surgical Raises $2.1M for its LapBox Tissue Containment System for Laparoscopic GYN Surgery

Israeli femtech startup Ark Surgical has secured $2.1 million in funding for its LapBox containment system for secure removal of large internal organs during laparoscopic GYN surgery. The financing was raised from investors of the Together equity crowdfunding platform alongside the Israeli Innovation Authority and NGT. Ark Surgical has completed the first-in-human (FIH) study demonstrating the safety and effectiveness of the LapBox. Approximately 600,000 hysterectomies…

Myovant and Pfizer Receive FDA Approval for MYFEMBREE, the First Once-Daily Treatment for Heavy Menstrual Bleeding Associated With Uterine Fibroids

An estimated 5 million women in the U.S. suffer from symptoms of uterine fibroids, and an estimated 3 million women are inadequately treated by current medical therapy and require further treatment. Uterine fibroids are noncancerous tumors that develop in or on the muscular walls of the uterus and are among the most common reproductive tract tumors in women. In addition to an individual’s genetic…